Fig. 4: Decreased mTORC1 activity in CRC cells treated with silmitasertib. | Cell Death & Disease

Fig. 4: Decreased mTORC1 activity in CRC cells treated with silmitasertib.

From: CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells

Fig. 4

a DLD-1 cells were incubated with 25 μM silmitasertib for 16 h. The levels of the indicated proteins were analyzed by western blot. b Cells were transfected with 100 nM of a specific siRNA for CK2α. The indicated proteins were analyzed by western blot. c Cells were transfected with the plasmid pCMV6-myr-AKT-1-CA-HA and then treated with 25 μM silmitasertib for 16 h. Protein levels were analyzed by western blot. d Levels of indicated proteins in cells transfected with the plasmids pCMV6-myr-AKT-1-CA-HA or pCMV6-myr-AKT-1-S129A-HA were analyzed by western blot. e Cell viability determined by MTS assay of cells transfected as in d. f Cell migration determined by transwell assay of cancer cells transfected as in d. Data represents the average ± SEM (n = 3); **p < 0.001; ****p < 0.0001; ns: not significant

Back to article page